Skip subpage navigation
Nov. 15-16, 2017
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Aug. 21, 2017
- Pre-Proposal Teleconference: Sept. 7, 2017 @ 12:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: August - September 2017
- UF BPA & UF ADP Quotes Due: Oct. 13, 2017
- P&T Committee Meeting: Nov. 15-16, 2017
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- Weight Loss Agents: Belviq, Belviq XR, Contrave, Qsymia, Saxenda, Xenical
- Oncological Agents - Multiple Myeloma: Alkeran, Farydak, Melphalan, Ninlaro, Pomalyst, Revlimid, Thalomid
|
- ArmonAir RespiClick
- Baxdela
- Benlysta
- Bevyxxa
- Cotempla XR ODT
- Duzallo
- Endari
- Fiasp
- Flolipid
- Fycompa O/S
- Gocovri
- Haegarda
- Idhifa
- Mavyret
- Nerlynx
- Nityr
- Symproic
- Trelegy Ellipta
- Tremfya
- Verzenio
- Vosevi
|
|
August 9-10, 2017
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: May 5, 2017
- Pre-Proposal Teleconference: May 18, 2017 @ 1200 Central
- Clinical/Cost Presentation Meeting Window: May - June, 2017
- UF BPA & UF ADP Quotes Due: June 30, 2017
- P&T Committee Meeting: August 9-10, 2017
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes
|
- Antiretrovirals - Combinations: Atripla, Complera, Genvoya, Odefsey, Stribild, Triumeq
- Antiretrovirals - Integrase Strand Transfer Inhibitors (INSTIs): Isentress, Tivicay, Vitekta
- Antiretrovirals - Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTIs): Descovy, Emtriva, Trizivir, Truvada, Viread, Ziagen
- Antiretrovirals - Other Agents: Aptivus, Crixivan, Edurant, Evotaz, Intelence, Invirase, Kaletra, Lexiva, Norvir, Prezcobix, Prezista, Rescriptor, Selzentry, Tybost, Viracept
- Corticosteroids/Immune Modulators - Hereditary Angioedema Agents: Berinert, Cinryze, Firazyr, Kalbitor, Ruconest
- Insulins - Basal: Basaglar Kwikpen U-100, Lantus, Lantus Solostar, Levemir, Levemir Flexpen, Levemir Flextouch, Toujeo Solostar, Tresiba Flextouch U-100, Tresiba Flextouch U-200
|
- AirDuo RespiClick
- Alunbrig
- Ingrezza
- Intrarosa
- Jadenu Sprinkle
- Kevzara
- Kisqali Femara Co-Pack
- Morphabond ER
- Mydayis ER
- Rydapt
- Siliq
- Syndros
- Tymlos
- Xadago
- Xatmep
- Zejula
|
|
May 10-11, 2017
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Feb. 15, 2017
- Pre-Proposal Teleconference: February 21, 2017 @ 2:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: March - April 2017
- UF BPA & UF ADP Quotes Due: April 3, 2017
- P&T Committee Meeting: May 10-11, 2017
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- Overactive Bladder Agents: Gelnique, Myrbetriq, Oxytrol, Toviaz, Vesicare - Solicitation Cancelled
- Ophthalmic-1 Agents: Bepreve, Emadine, Lastacaft, Pataday, Pazeo
- Pulmonary Miscellaneous: Esbriet, Ofev
|
- Arymo ER
- Austedo
- Dupixent
- Emflaza
- Eucrisa
- Kisqali
- Rhofade
- Trulance
- Xermelo
- Xultophy
|
|
Feb. 8-9, 2017
- Clinical/Cost Presentation Meeting Window: November - December 2016
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- Antibiotics - Tetracyclines
- Hepatitis C Agents - Direct Acting Agents
- Ophthalmic-1 Agents - Antihistamine Mast Cell Stabilizers: Solictation Cancelled
|
- Adlyxin
- Basaglar
- BromSite
- Rayaldee
- Rubraca
- Soliqua
- Vemlidy
|
|
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024